Leukemia | Topics

 
ELEVATE-RR: Efficacy Data
May 24, 2022

Experts discuss efficacy data from the ELEVATE-RR trial on the Bruton tyrosine kinase inhibitors acalabrutinib vs ibrutinib.

Patient Characteristics in ELEVATE-RR
May 24, 2022

Dr Bishop comments on the characteristics of the patients with CLL who were enrolled in the ELEVATE-RR trial.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study
May 23, 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Cross Q&A: Team Moffitt Marrowvingians
May 23, 2022

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

FDA Approved Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022

Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.

Expert Commentary on the Product Profile of Asciminib
April 08, 2022

In an interview with ONCOLOGY®, Elizabeth Travers, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of asciminib as therapy for patients with chronic myeloid leukemia.

Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLL
January 26, 2022

Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Multiprong Leukemia Efforts Boost the Atlantic Health System Heme/Onc Program
January 24, 2022

An upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.

Matthew S. Davids, MD, MMSc, Discusses Rationale for the MAJIC Study of Venetoclax Plus Acalabrutinib in CLL
January 12, 2022

Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Acalabrutinib Plus Venetoclax To Be Evaluated in Treatment-Naive CLL/SLL
December 27, 2021

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.